Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.61 |
| ▸ | SCD | O00767 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.44 |
| ▸ | FADS1 | O60427 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12359213 | 0.87 | TRPV1 (0.60) | TRPV1SCDCHEK2 | |
| SCHEMBL12358709 | 0.86 | TRPV1 (0.54) | TRPV1SCDCHEK2 | |
| SCHEMBL12358843 | 0.86 | SCD (0.54) | TRPV1SCDCHEK2FADS1 | |
| SCHEMBL12358864 | 0.85 | TRPV1 (0.46) | TRPV1SCDCHEK2 | |
| SCHEMBL12359206 | 0.84 | TRPV1 (0.62) | TRPV1SCDCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1798530 | 0.84 | TRPV1 (0.86) | TRPV1 | |
| SCHEMBL2247070 | 0.84 | TRPV1 (0.68) | TRPV1 | |
| SCHEMBL1798533 | 0.84 | TRPV1 (0.86) | TRPV1 | |
| SCHEMBL1798681 | 0.84 | TRPV1 (0.68) | TRPV1SCD | |
| SCHEMBL12358815 | 0.83 | CHEK2 (0.49) | TRPV1SCDCYP3A4CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-04 | — | — | US | disclosed |
| US-20110190364-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-04 | — | — | US | disclosed |
| US-7951829-B2 | Benzimidazole modulators of VR1 | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-31 | — | — | US | disclosed |
| US-20070259936-A1 | Benzimidazole Modulators of VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190364-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | VRK1, VRK2, VIL1 | TRPV1 29/4885SCD 4754/4885CYP3A4 73/4885 |
| US-20070259936-A1 | Benzimidazole Modulators of VR1 | VRK1, VRK2, VIL1 | TRPV1 29/4885SCD 4754/4885CYP3A4 73/4885 |
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | VRK1, VRK2, VIL1 | TRPV1 29/4885SCD 4754/4885CYP3A4 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.